Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐ACT study data

BACKGROUND: The X‐ACT study aimed to examine the effect of omalizumab treatment on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to high doses of H(1)‐antihistamines. METHODS: In X‐ACT, a phase III, double‐blind, placebo‐controlled study, CSU patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Staubach, P., Metz, M., Chapman‐Rothe, N., Sieder, C., Bräutigam, M., Maurer, M., Weller, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836932/
https://www.ncbi.nlm.nih.gov/pubmed/29058822
http://dx.doi.org/10.1111/all.13339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836932/
https://www.ncbi.nlm.nih.gov/pubmed/29058822
http://dx.doi.org/10.1111/all.13339

Ejemplares similares